Cerebrovascular disease in senile patient (clinical case)
https://doi.org/10.21518/2079-701X-2021-2-103-110
Abstract
The article presents a clinical observation of a comorbid elderly patient with complaints typical for chronic cerebrovascular disease. A careful analysis of the clinical picture and a thorough assessment of the patient’s condition, including testing of cognitive and non-cognitive neuropsychiatric functions, made it possible to identify characteristic syndromes of cerebrovascular disease, which was additionally confirmed by the magnetic resonance imaging. The patient’s therapy regimen was optimized with an emphasis on clinically and pathogenetically justified methods taking into account the main clinical syndromes. Patient’s follow-up assessment has shown that the treatment was accompanied by significant positive dynamic, in both cognitive and emotional signs and symptoms. The article discusses the epidemiology of cerebrovascular diseases, their relationship with other geriatric syndromes in elderly and senile people. The main problems associated with the therapy of cerebrovascular diseases in elderly patients and the ways to eliminate them are discussed.
About the Authors
M. A. Cherdak
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Maria A. Cherdak, Cand. of Sci. (Med.), Assistant Professor of the Department of Age-related Diseases
1, Ostrovityanov St., Moscow, 117997
E. A. Mkhitaryan
Pirogov Russian National Research Medical University; Russian Clinical and Research Center of Gerontology
Russian Federation
Russian Federation
Elen A. Mkhitaryan, Cand. of Sci. (Med.), Associate Professor of the Department of Age-related Diseases, Pirogov Russian National Research Medical University; Neurologist, Senior Researcher of the Laboratory of General Geriatrics and Neurogeriatrics, Russian Clinical and Research Center of Gerontology
1, Ostrovityanov St., Moscow, 117997
16, 1st Leonov St., Moscow, 129226
References
1. Nedogoda S.V., Tsoma V.V., Chumachek E.V., Smirnova V.O., Palashkin R.V. Vascular ageing in elderly patients with metabolic syndrome. Rossiiskii zhurnal geriatricheskoi meditsiny = Russian Journal of Geriatric Medicine. 2020;(1):74–80. (In Russ.) doi: 10.37586/2686-8636-1-2020-74-80.
2. Hachinski V. Vascular dementia: a radical redefinition. Dementia. 1994;5(3–4):130–132. doi: 10.1159/000106709.
3. Zakharov V.V. Evolution of cognitive deficit: mild and moderate cognitive impairments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2):16–21. (In Russ.) doi: 10.14412/2074-2711-2012-376.
4. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16(3):391–460. doi: 10.1002/alz.12068.
5. Cherdak M.A. Mixed dementia in stroke patient. Rossiiskii zhurnal geriatricheskoi meditsiny = Russian Journal of Geriatric Medicine. 2020;(3):236–242. (In Russ.) doi: 10.37586/2686-8636-3-2020-236-242.
6. Samorodskaya I.V., Andreev E.M., Zaratyants O.V., Kosivtsova O.V., Kakorina E.P. Cerebrovascular disease mortality rates in the population over 50 years of age in Russia and the USA over a 15-year period. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(2):15–24. (In Russ.) doi: 10.14412/2074-27112017-2-15-24.
7. Kulesh A.A., Shestakov V.V. Vascular cognitive impairment, no dementia: diagnosis, prognosis, treatment, and prevention. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(3):68–75. (In Russ.) doi: 10.14412/2074-27112017-3-68-75.
8. Dichgans M., Leys D. Vascular Cognitive Impairment. Circ Res. 2017;120(3):573–591. doi: 10.1161/CIRCRESAHA.116.308426.
9. Oganov R.G., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Barbarash O.L., Boytsov S.A. et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2019;18(1):5–66. (In Russ.) doi: 10.15829/1728-8800-2019-1-5-66.
10. Sachdev P., Kalaria R., O’Brien J., Skoog I., Alladi S., Black S.E. et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206–218. doi: 10.1097/WAD.0000000000000034.
11. Ghafar M.Z.A.A., Miptah H.N., O’Caoimh R. Cognitive screening instruments to identify vascular cognitive impairment: A systematic review. Int J Geriatr Psychiatry. 2019;34(8):1114–1127. doi: 10.1002/gps.5136.
12. Emdin C.A., Rothwell P.M., Salimi-Khorshidi G., Kiran A., Conrad N., Callender T. et al. Blood Pressure and Risk of Vascular Dementia: Evidence From a Primary Care Registry and a Cohort Study of Transient Ischemic Attack and Stroke. Stroke. 2016;47(6):1429–1435. doi: 10.1161/STROKEAHA.116.012658.
13. Kosenkov A.N., Vinogradov R.A., Drakin O.V. Influence of cerebral ischemia on cognitive disorders in patients with carotid arteries atherosclerosis. Kardiologiya i serdechno-sosudistaya khirurgiya = Russian Journal of Cardiology and Cardiovascular Surgery. 2016;9(3):4–8. (In Russ.) doi: 10.17116/kardio2016934-8.
14. Banach M., Serban C., Sahebkar A., Mikhailidis D.P., Ursoniu S., Ray K.K. et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229. doi: 10.1186/s12916-015-0459-4.
15. Poly T.N., Islam M.M., Walther B.A., Yang H.C., Wu C.C., Lin M.C., Li Y.C. Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies. Neuroepidemiology. 2020;54(3):214–226. doi: 10.1159/000503105.
16. Pronin I.N., Zakharova N.E., Fadeeva L.M., Pronin A.I., Shults E.I., Batalov A.I. Pulse Sequence SWI/SWAN in Diagnosis of Microhemorrhage and Cerebral Vascular Micromalformations. Onkologicheskiy zhurnal: luchevaya diagnostika, luchevaya terapiya = Journal of Oncology: Diagnostic Radiology and Radiotherapy. 2018;1(3):49–57. (In Russ.) doi: 10.37174/2587-75932018-1-3-49-57.
17. Smith E.E., Saposnik G., Biessels G.J., Doubal F.N., Fornage M., Gorelick P.B. et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e44–e71. doi: 10.1161/STR.0000000000000116.
18. Northey J.M., Cherbuin N., Pumpa K.L., Smee D.J., Rattray B. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med. 2018;52(3):154–160. doi: 10.1136/bjsports-2016-096587.
19. Singh B., Parsaik A.K., Mielke M.M., Erwin P.J., Knopman D.S., Petersen R.C., Roberts R.O. Association of mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;39(2):271–282. doi: 10.3233/JAD-130830.
20. Chandler M.J., Parks A.C., Marsiske M., Rotblatt L.J., Smith G.E. Everyday Impact of Cognitive Interventions in Mild Cognitive Impairment: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2016;26(3):225–251. doi: 10.1007/s11065-016-9330-4.
21. Livingston G., Huntley J., Sommerlad A., Ames D., Ballard C., Banerjee S. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi: 10.1016/S0140-6736(20)30367-6.
22. Jin B.R., Liu H.Y. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis. Neural Regen Res. 2019;14(5):805–816. doi: 10.4103/1673-5374.249228.
23. Stakhovskaya L.V., Shamalov N.A., Khasanova D.R., Melnikova E.V., Agafiina A.S., Golikov K.V. et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3):55–65. (In Russ.) doi: 10.17116/jnevro20171173255-65.
24. Bogolepova A.N. The role of Neurotrophic factors in development of poststroke depression. Consilium Medicum. 2019;21(2):18–23. (In Russ.) doi: 10.26442/20751753.2019.2.190304.
25. Abduraimova S.K., Zakharov V.V., Kabaeva A.R. Cognitive, emotional, and behavioral disorders in hypertensive patients. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(4):116–122. (In Russ.) doi: 10.14412/2074-2711-2018-4-116-122.
26. Rawle M.J., Cooper R., Kuh D., Richards M. Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study. J Am Geriatr Soc. 2018;66(5):916–923. doi: 10.1111/jgs.15317.
27. Gnjidic D., Hilmer S.N., Blyth F.M., Naganathan V., Waite L., Seibel M.J. et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–995. doi: 10.1016/j.jclinepi.2012.02.018.
28. Wiese B.S. Geriatric depression: the use of antidepressants in the elderly. BC Med J. 2011;53(7):341–347. Available at: https://bcmj.org/sites/default/files/BCMJ_53_Vol7_depression.pdf.
Review
For citations:
Cherdak MA, Mkhitaryan EA. Cerebrovascular disease in senile patient (clinical case). Meditsinskiy sovet = Medical Council. 2021;(2):103-110. (In Russ.) https://doi.org/10.21518/2079-701X-2021-2-103-110
Views:
673
Email this article 